A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: Case series

Neuropsychobiology

Volumn 51, Issue 4, 2005, Pages 239-242

  Toren, Paz ^a,e   Ratner, Sharon ^a   Laor, Nathaniel ^a,d   Lerer Amisar, Dana ^b   Weizman, Abraham ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Yale Child Study Center ^*  (Israel)

Author keywords

Attention deficit hyperactivity disorder; Enuresis; Norepinephrine; Reboxetine

Indexed keywords

REBOXETINE;

ABDOMINAL PAIN; ADOLESCENT; APPETITE DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; COMORBIDITY; CONSTIPATION; DRUG EFFECT; DRUG MONITORING; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MOOD DISORDER; NOCTURNAL ENURESIS; PRIORITY JOURNAL; RECORDING; SCHOOL CHILD; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; TRICHOTILLOMANIA;

EID: 22144462107     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085726     Document Type: Article

References (33)

1. Owens RG, Karram MM: Comparative tolerability of drug therapies used to treat incontinence and enuresis. Drug Saf 1998;19:123-139.
2. Fournier JP, Garfinkel BD, Bond A, Beauchesne H, Shapiro SK: Pharmacological and behavioral management of enuresis. J Am Acad Child Adolesc Psychiatry 1987;26:849-853.
3. Lackgren G, Hjalmas K, Van-Gool, Von Gontard A, De Gennaro M, Lottmann H, Terho P: Nocturnal enuresis: A suggestion for a European treatment strategy. Acta Paediatr 1999;88:679-690.
4. Mikkelsen EJ: Enuresis and encopresis: Ten years of progress. J Am Acad Child Adolesc Psychiatry 2001;40:1146-1158.
5. Mikkelsen EJ, Rapoport JL: Enuresis: Psychopathology, sleep stage, and drug response. Urol Clin North Am 1980;7:361-377.
6. Rapoport JL, Mikkelsen EJ, Zavadil A, Nee L, Gruenau C, Mendelson W, Gillin JC: Childhood enuresis. II. Psychopathology, tricyclic concentration in plasma, and antienuretic effect. Arch Gen Psychiatry 1980;37:1146-1152.
7. Hunsballe JM, Rittig S, Pedersen EB, Olesen OV, Djurhuus JC: Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. J Urol 1997;158:830-836.
8. Rushton HG: Nocturnal enuresis: Epidemiology, evaluation, and currently available treatment options. J Pediatr 1989;144:691-696.
9. Labellarte MJ, Crosson JE, Riddle MA: The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003;42:642-650.
10. Feeney DJ, Klykylo WM: SSRI treatment of enuresis. J Am Acad Child Adolesc Psychiatry 1997;36:1326-1327.
11. Murry ME: Treatment of enuresis with paroxetine (letter). J Dev Behav Pediatr 1997;18:435-436.
12. Sprenger D: Sertraline for nocturnal enuresis. J Am Acad Child Adolesc Psychiatry 1997;36:304-305.
13. Kano K, Arisaka O: Fluvoxamine and enuresis. J Am Acad Child Adolesc Psychiatry 2000;39:1464-1466.
14. Kano K, Arisaka O: More on fluvoxamine and enuresis. J Am Acad Child Adolesc Psychiatry 2001;40:865.
15. Toren P, Eldar S, Laor N, Wolmer L, Samuel E, Weizman R: Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: An open-label pilot study. Hum Psychopharmacol 2001;16:327-332.
16. Toros F, Erdogan K: Paroxetine-induced enuresis. Eur Psychiatry 2003;18:43-44.
17. Took KJ, Buck BJ: Enuresis with combined risperidone and SSRI use. J Am Acad Child Adolesc Psychiatry 1996;35:840-841.
18. Kent JM: SNaRIs, NaSSAs, and NaRIs: New agents for treatment of depression. Lancet 2000;355:911-918.
19. Versiani M, Amin M, Chouinard G: Double-blind, placebo-controlled study with reboxetine in inpatients with sever major depressive disorder. J Clin Psychopharmacol 2000;20:28-34.
20. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-1147.
21. Otka JE, Mercadante MT, Scahill L, Leckman JF: Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder (letter). J Child Adolesc Psychopharmacol 2001;11:203-204.
22. Ratner S, Laor N, Bronstein Y, Weizman A, Toren P: Six-week open-label reboxetine treatment in children and adolescents with attention deficit/hyperactivity disorder. Submitted.
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4, DSM-IV-TR. Washington, APA, 2000.
24. Brunnello N, Racagni G: Rationale for the development of noradrenaline reuptake inhibitors. Hum Psychopharmacol 1998;13:S13-S19.
25. Su L, Guess HA, Girman CJ, Jacobsen SJ, Oesterling JE, Panser LA, Lieber MM: Adverse effects of medications on urinary symptoms and flow rate: A community-based study. J Clin Epidemiol 1996;49:483-487.
26. Anderson KE: Pharmacology of lower urinary tract smooth muscles and penile erection tissues. Pharmacol Rev 1993;45:253-308.
27. Szabadi E: Doxazosin for reboxetine-induced urinary hesitancy. Br J Psychiatry 1998;173:441-442.
28. Kasper S: Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: A case study. Psychopharmacology 2002;159:445-446.
29. Kasper S, Wolf R: Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. Eur Neuropsychopharmacol 2002;12:119-122.
30. Demyttenaere K, Huygens R, VanBuggenhout R: Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy. Int Clin Psychopharmacol 2001;16:353-355.
31. Penttila J, Syvalahti E, Hinkka S, Kuusela T, Scheinin H: The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001;154:343-349.
32. Danuser H, Bemis K, Thor KB: Pharmacological analysis of the noradrenergic control of central sympathetic and somatic reflexes controlling the lower urinary tract in the anesthetized cat. J Pharmacol Exp Ther 1995;274:820-825.
33. Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC; Duloxetine Urinary Incontinence Study Group: Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003;170:1259-1263.